We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ASML:EURONEXT AMSTERDAMASML Holding NV Analysis

Data as of 2026-03-09 - not real-time

$1,292.80

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

ASML’s shares have slipped below the 20‑day (≈1,430) and 50‑day (≈1,340) moving averages, landing near the identified support level of 1,287. The RSI of 38 signals a modest oversold condition, while the MACD histogram remains negative, suggesting short‑term bearish momentum despite an overall bullish trend and a rising volume profile. Recent earnings beat, record EUV system orders and an “extremely bullish” sentiment shift on social platforms have sparked a 5‑plus‑percent pre‑market rally, even as the company announced a 1,700‑person layoff to streamline costs.
Fundamentally, ASML delivers exceptional profitability – gross margin above 52%, operating margin over 35% and a ROE north of 50% – and maintains a strong balance sheet with cash exceeding €13 bn and modest leverage (debt‑to‑equity ~24%). However, the trailing P/E of ~45 sits well above the industry average of ~36, and the DCF‑derived fair value of roughly €495 is far below the current price, flagging potential overvaluation. The dividend remains modest (≈0.7%) but is comfortably covered given the low payout ratio and robust cash generation, supporting its sustainability.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price testing support near €1,287 with rising volume
  • Positive earnings surprise and record EUV orders
  • Technical oversold signal (RSI ~38) despite bearish MACD

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained high margins and ROE >50%
  • Forward P/E compression to ~30 indicating earnings acceleration
  • Dominant EUV position limiting competitive risk

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strategic moat in semiconductor lithography
  • Strong cash generation supporting dividend and R&D
  • Long‑term secular demand for advanced nodes

Key Metrics & Analysis

Financial Health

Revenue Growth4.90%
Profit Margin29.42%
P/E Ratio45.0
ROE50.46%
ROA14.25%
Debt/Equity23.92
P/B Ratio21.9
Op. Cash Flow$12.7B
Free Cash Flow$10.9B
Industry P/E36.2

Technical Analysis

TrendBullish
RSI37.8
Support$1,286.67
Resistance$1,547.22
MA 20$1,429.60
MA 50$1,340.04
MA 200$995.46
MACDBearish
VolumeIncreasing
Fear & Greed Index68.77

Valuation

Fair Value$495.68
Target Price$1,462.02
Upside/Downside13.09%
GradeOvervalued
TypeGrowth
Dividend Yield0.68%

Risk Assessment

Beta1.48
Volatility40.64%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.